FIELD: chemistry.
SUBSTANCE: present invention relates to use of sodium 4,4'-(propanediamido)dibenzoate as an anti-steatosis agent, supporting a beam structure of liver parenchyma, preserving portal tracts without fibrosis, preventing periportal necroinflammatory activity.
EFFECT: wider range of low-toxicity anti-stethosics, having protective and regenerative properties, causing significantly more pronounced and early reparative and regenerative exposure on the liver.
1 cl, 1 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF SIMULATING NON-ALCOHOLIC FATTY LIVER DISEASE IN RATS | 2015 |
|
RU2600476C1 |
MEANS FOR NON-ALCOHOLIC FATTY LIVER DISEASE TREATMENT AND PREVENTION | 2016 |
|
RU2644282C2 |
METHOD OF MODELING NON-ALCOHOLIC STEATOHEPATITIS IN RATS | 2009 |
|
RU2394281C1 |
METHOD OF SIMULATING NON-ALCOHOLIC STEATOHEPATITIS IN RATS | 2015 |
|
RU2598351C1 |
METHOD FOR STEP-BY-STEP MODELING OF NONALCOHOLIC FATTY PANCREATIC DISEASE IN RATS | 2021 |
|
RU2770555C1 |
METHOD FOR MODELLING NON-ALCOHOLIC FATTY LIVER DISEASE BY DIET RICH IN FRUCTOSE | 2019 |
|
RU2728418C1 |
METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE AND TYPE 2 DIABETES MELLITUS | 2018 |
|
RU2706026C1 |
METHOD OF SIMULATING MULTIPLE ORGAN PATHOLOGY IN RATS | 2011 |
|
RU2453002C1 |
METHOD OF TREATING STEATOHEPATOSIS IN EXPERIMENTAL ANIMALS | 2023 |
|
RU2811886C1 |
METHOD FOR PREDICTING SEVERE HEPATIC FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE | 2021 |
|
RU2765847C1 |
Authors
Dates
2019-10-03—Published
2019-03-18—Filed